EIT KIC 2022

IMPACCT研究将调查是否有可能使用一种新的诊断测试来识别和分类预后不良和发生新感染风险较高的败血症患者。IMPACCT研究由英国伦敦帝国理工学院赞助和管理，首席研究员安东尼·戈登教授。脓毒症是指严重感染导致器官衰竭。这是一个主要的全球医疗保健问题。最近的研究表明，全世界每年有多达4900万例败血症，导致1100万人死亡。随着脓毒症治疗的改善，现在更多的患者从脓毒症的早期阶段恢复，但重复发生是一个主要问题。脓毒症患者通常会经历免疫系统减弱，即免疫抑制。现在认为这是很大一部分败血症患者的一个重要特征，并导致这些患者预后不良。目前尚无临床试验来评估败血症患者的免疫功能。IMPACCT将评估产生免疫谱图（IPP）的基于rna的快速诊断测试是否可以识别免疫抑制且预后不良风险较高的脓毒症患者。这是一项观察性研究，没有干预措施或新的治疗方法，也没有改变患者的标准护理和治疗。在两年的时间里，这项研究将在英国、法国和瑞典的医院招募600名患者。参与者将是正在或曾经接受过疑似败血症治疗、正在或已经接受器官支持的重症监护成年患者。患者将在ICU住院超过48小时，少于120小时（5天），预计需要在能够提供器官支持的环境中持续护理至少一天。研究小组将收集患者在医院治疗期间的医疗状况数据，并对参与者的血液样本进行临床诊断测试。将在研究期间的3个时间点从患者身上采集血液样本，并将从留置线中采集血液样本。检测结果不会与研究团队共享，也不会影响患者的护理。纳入后90天，将与患者联系，完成关于他们的健康和任何新感染的日记。

The IMPACCT study will investigate whether it is possible to use a new diagnostic test to identify and classify patients with sepsis who are at higher risk of poor outcomes and developing new infections. The IMPACCT study is being sponsored and managed by Imperial College London in the UK and the Chief Investigator is Professor Anthony Gordon. Sepsis is when severe infection leads to organ failure. It is a major global healthcare problem. Recent studies suggest as many as 49 million cases of sepsis worldwide each year leading to 11 million deaths. As sepsis care has improved more patients now recover from the early phases of sepsis but repeat occurrences are a major problem. Patients with sepsis often experience weakening of their immune systems known as immune suppression. This is now recognised as an important feature in a large proportion of patients who have sepsis and it leads to poor outcomes for these patients. At present there is no clinical test to assess the immune function of patients who have sepsis. IMPACCT will evaluate if a rapid RNA-based diagnostic test that produces an Immune Profiling Panel (IPP) can identify patients with sepsis who are immunosuppressed and at higher risk of poor outcomes. It is an observational study with no intervention or novel treatment introduced and no change to patients’ standard care and treatment when taking part. Over a 2-year period, the study will recruit 600 patients in hospitals in the UK, France, and Sweden.Participants will be adult patients in intensive care who are being, or have been, treated for suspected sepsis and are receiving, or have received, organ support. The patients will have been admitted to an ICU for over 48hours and less than 120 hours (5 days) and are expected to require ongoing care in an environment capable of providing organ support for at least one more calendar day. The study research team will collect data on the patient’s medical condition throughout their treatment in hospital and will conduct a clinical diagnostic test on participants’ blood samples. Blood samples will be taken from patients at 3 time points during the study and will be taken from indwelling lines where present. Test results will not be shared with the research team or influence patients’ care. Patients will be contacted 90 days after inclusion to complete a diary regarding their wellbeing and any new infections.